Currently, Wegovy is the only treatment with published long-term cardiovascular outcome data
It is a dual-action medication that works on both GLP-1 and GIP receptors
For patients who have missed multiple consecutive doses or have been off tirzepatide for several weeks, consultation with the prescribing healthcare provider is essential before resuming treatment
Ambas molculas pertenecen a la clase de medicamentos que ha revolucionado en los ltimos aos la prctica mdica en obesidad, llamados anlogos del pptido similar al glucagn tipo 1 (GLP-1), respaldados ampliamente por ensayos clnicos y datos clnicos
The body loses adaptation quickly once the medication clears
This includes reporting any new symptoms promptly, attending scheduled follow-up appointments, and coordinating care between primary care providers, endocrinologists, and eye care specialists when appropriate